fda glp-1 warning news november 2025 takes aim at telehealth companies for promoting unofficial weight loss drug dupes Trends In FDA FY 2025

Total weight loss from baseline to week 52 was 6.7% in the placebo group, 10.9% with exercise alone, 13.4% with liraglutide alone, and 15.7% with combination therapy

Higgins V, Asgari S, Hamilton JK, Wolska A, Remaley AT, Hartmann B, et al

It remains under investigation in clinical trials registered on ClinicalTrials.gov and the EU Clinical Trials Register, and is not licensed for prescription or self-administration outside of formally approved research settings

In cases 4 to 7 & 9, without a history of GI surgery treatment primarily consisted of lifestyle interventions and metformin, and the dosage was titrated according to the clinical response to maximum dose of 2 g daily